Liprolog Kwikpen (Insulin Lispro)

Insulin lispro binds to insulin receptors on muscle and fat cells, quickly stimulating glucose uptake and suppressing liver glucose production. Its modified structure allows rapid dissociation from hexamers, producing a faster onset of action than regular human insulin, which helps match insulin delivery to carbohydrate intake.

The dose of insulin lispro is individualized. A qualified prescriber determines the amount, timing, and frequency based on the patient’s blood‑glucose patterns, carbohydrate intake, and overall treatment plan. Patients should follow the prescribing clinician’s instructions and adjust only under medical guidance.

Insulin lispro is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It may be used during pregnancy or lactation when the expected benefit outweighs potential risk, but treatment should be supervised by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Insulin lispro, the active ingredient in Liprolog Kwikpen, has a similar onset and duration to other rapid‑acting analogs such as insulin aspart and insulin glulisine. Differences are mainly in formulation and device design; the pen offers convenient, pre‑measured dosing, while clinical efficacy and safety profiles are comparable when used correctly.

Liprolog Kwikpen should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the pen. Once in use, the pen can be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which it must be discarded.

The pen is designed for subcutaneous injection. After selecting the prescribed dose, the user inserts a new needle, primes the pen, and injects into the abdomen, thigh, or upper arm at a 90‑degree angle. Proper technique and site rotation help reduce injection‑site complications.

The most serious risks include severe hypoglycemia, which can cause confusion, loss of consciousness, or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia and seek immediate medical attention for any severe allergic response.

Liprolog Kwikpen is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of the pen’s excipients. It should also be avoided in patients with severe hypoglycemia unawareness unless closely supervised, and in those for whom rapid‑acting insulin is not appropriate as determined by their clinician.